Skip to main content
VTRS
NASDAQ Life Sciences

Viatris Refinances ¥40 Billion Term Loan, Extending Maturity to 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$16.18
Mkt Cap
$18.99B
52W Low
$8.625
52W High
$17.53
52W Position info
88% above low
Off High info
7.7% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

VTRS sits 88% above its 52-week low of $8.625.

Summary

Viatris refinanced its ¥40 billion term loan, extending the maturity to 2029, which is a positive step for its debt management and financial stability.


Key Events · Financing and Capital Events · VTRS

  • Refinances ¥40 Billion Term Loan

    Viatris entered into an amended and restated term loan credit agreement for a ¥40,000,000,000 senior unsecured term loan facility.

  • Extends Debt Maturity

    The new agreement refinances an existing ¥40 billion facility and extends its maturity by three years, from July 1, 2026, to July 1, 2029.

  • Interest Rate Tied to Debt Rating

    The loan's interest rate is TIBO Rate plus 1.10% per annum, with the applicable margin fluctuating based on Viatris's long-term unsecured senior debt rating.

  • Standard Financial Covenants

    The agreement includes a financial covenant requiring a consolidated leverage ratio no greater than 3.75 to 1.00, with a temporary increase to 4.25 to 1.00 following a Qualified Acquisition.


Analysis · VTRS · Life Sciences

Viatris Inc. has amended and restated its ¥40 billion unsecured term loan credit agreement, effectively refinancing the existing facility and extending its maturity by three years to July 1, 2029. This move is a positive for the company's debt management, ensuring continued access to capital and pushing out a significant debt maturity. The loan bears interest at TIBO Rate plus 1.10%, with the rate tied to the company's debt rating.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VTRS was trading at $16.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19B. The 52-week trading range was $8.63 to $17.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTRS - Latest Insights

VTRS
Nov 12, 2026, 4:16 PM EST
Filing Type: SC TO-T/A
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $20.90 info
Change: +$0.2104 (+1%) info
Market Cap: $23.869B info
VTRS
Nov 05, 2026, 9:23 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.40
Real-time Price: $20.90 info
Change: +$1.50 (+8%) info
Market Cap: $23.869B info
VTRS
Nov 05, 2026, 7:45 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.33
Real-time Price: $20.90 info
Change: +$1.57 (+8%) info
Market Cap: $23.869B info
VTRS
Nov 05, 2026, 6:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.36
Real-time Price: $20.90 info
Change: +$1.54 (+8%) info
Market Cap: $23.869B info
VTRS
Oct 30, 2026, 7:40 AM EDT
Filing Type: SC TO-T
Importance Score:
8
Price at Filing: $19.30
Real-time Price: $20.90 info
Change: +$1.60 (+8%) info
Market Cap: $23.869B info